View Schedule

34th Annual Meeting & Pre-Conference Programs Schedule

no_symbol.pngPresentations with this symbol were not permitted to be posted.

Wednesday, Nov. 6, 2019
World Immunotherapy Council’s 3rd Young Investigator Symposium
Time:
Location:
7:30 a.m. – 1:00 p.m.
Cherry Blossom Ballroom

Adoptive T Cell Therapies
7:30 a.m.

Longitudinal Tracking of WT1-specific T-cells Allows to Generate a Library of WT1-specific TCRs, for TCR Gene Editing of Acute Leukemia
Eliana Ruggiero, PhD – San Raffaele Scientific Institute (ATTACK)

7:45 a.m.

no_symbol.pngArming T cells with Chemokine Receptors Enables Adoptive T cell Therapy of Cancer
Sebastian Kobold, MD – Klinikum der Universität München (CDDF)

8:00 a.m.

no_symbol.pngTargeting CD20 – A Functional Comparison of TCR and CAR Transduced T cells
Tassilo Wachsmann, MSc – Leiden University Medical Center (DTIM)

8:15 a.m.
Genetic Manipulation of Antitumor T cells to Elicit a Durable Clinical Response in Adoptive Immunotherapy
Yuki Kagoya, MD, PhD – The University of Tokyo Hospital (JACI)

8:30 a.m.
Engineering Adoptive T cell Therapy to Overcome Immune Suppression in Ovarian Cancer
Kristin Anderson, PhD – Fred Hutchinson Cancer Research Center (SITC)

8:45 a.m. Combination of Short-lived and Extended Half-life Target Modules for Optimized UniCAR T cell Therapy
Claudia Arndt, PhD – Helmholtz-Zentrum Dresden-Rossendorf (TIMO)

Gene Profiling and Identification of Biomarkers

9:00 a.m. no_symbol.pngImmune Monitoring for Clarifying Optimal Immunotherapy
Hye Kim, MD, PhD – Division of Medical Oncology, Yonsei Cancer Center (KCA)

9:15 a.m. no_symbol.pngHuman CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma
Haoyu Sun, PhD – University of Science and Technology of China (TIBIT)

9:30 a.m. Gene Profile Analysis of Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors
Domenico Mallardo, MD – Istituto Nazionale Tumori - IRCCS - "Fondazione G.Pascale" (SCITO)

9:45 a.m. Genomic Instability, Tumor Mutation Burden and Biomarkers in Lung                     Cancer and Other Solid Tumors
Kai He, MD, PhD – Ohio State University James Cancer Hospital (CAHON)

10:00 a.m.

NY-ESO-1- and Melan-A-reactive T-cells Disappear from the Circulation                 in Clinical Responders to PD-1 Blockade in Melanoma
Kilian Wistuba-Hamprecht, Dr. rer. nat – Department of Dermatology, University Hospital Tübingen (PIVAC)

10:15 a.m.   Break

Immune Checkpoint Inhibitors

10:30 a.m. Low Molecular Weight Heparin Augments the Effectiveness of Immune Checkpoint Inhibitors in Vitro and in Vivo
Panagiotis Sarantis, MSc – Medical School of Athens (University of Athens)

10:45 a.m. The Clinical Utility and Safety of Immune Check Point Inhibitors (ICI) - Multicentric Data from India
George Abraham, MD – Tata Memorial Centre (I-OSI)

11:00 a.m. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Davis Torrejon, MD – UCLA Hematology-Oncology (GETICA)

11:15 a.m. Novel Immunotherapies and Regional Chemotherapy in Uveal Melanoma
Gitta Panczel, MD – National Institute of Oncology (National Institute of Oncology, Budapest)

11:30 a.m. Rational Combination of a Small Inhibitor and Immune Checkpoint Blockade in Hepatocellular Carcinoma Preclinical Models
Timothy Shuen, PhD – National Cancer Centre Singapore (SSO-CIC)

Novel Treatments

11:45 a.m.

Reprogramming CD8 Cells into Metabolically Fit Stem Cell Memory with Superior Therapeutic Activity by MEK1/2 Manipulation
Vivek Verma, PhD – Georgetown Lombardi Comprehensive Cancer Center (TVACT)

12:00 p.m.
Podocalyxin is a Therapeutic Target in Carcinoma
Diana Canals Hernaez, BSc – The University of British Columbia (CCIC)

12:15 p.m. Manipulation of Lipid Metabolism in Monocyte-derived DC Enhance Their Interaction with Natural Killer Cells
Chiara Massa, PhD – Martin Luther University Halle-Wittenberg (GIS)

12:30 p.m. The Role of Phytocannabinoids in Cancer
Nadine Hall, BSc – St. George's, University of London (ICVI)

12:45 p.m. Antibody Targeting of Tumor Associated Macrophages in Pancreatic Cancer and Melanoma Remodel the Tumor Microenvironment and Revives Immune Targeting of Tumor Cell
Dhifaf Sarhan, PhD – Karolinska Institutet (SNIC)


Novel Multi-Targeted Therapeutic Platforms
Time:
Location:

2:00 - 6:30 p.m.
Cherry Blossom Ballroom

Session 1: Basics of Multi-Targeted Therapeutic Platforms

2:00 p.m.

Introduction

2:05 p.m.

Overview of Different Platform Structures

2:25 p.m.

no_symbol.pngCytokine Fusions
Raphael Clynes, MD, PhD – Xencor, Inc.

2:45 p.m.

Multi-Targeted CAR T cells
Marcela V. Maus, MD, PhD – Massachusetts General Hospital

3:05 p.m. no_symbol.pngBiTEs, TriKEs, TriNKETs
Jeffrey S. Miller, MD -- University of Minnesota

3:25 p.m. Break

3:40 p.m. no_symbol.pngPros and Cons of Multi-Targeted Therapeutics Panel Discussion
Panelists:
Raphael Clynes, MD, PhD – Xencor, Inc.
David S. Hong, MD – The University of Texas MD Anderson Cancer Center
Israel Lowy, MD, PhD – Regeneron Pharmaceuticals
Marcela V. Maus, MD, PhD – Massachusetts General Hospital
Jeffrey S. Miller, MD -- University of Minnesota

Session 2: Novel Platforms and Innovation
4:15 p.m Contextual reprogramming of T cells for multi-targeted therapeutics: checkpoint blockade, immune resilience, and stemness to overcome immune resistance and reduce toxicity, all in one cell product
Francesco M. Marincola, MD – Refuge Biotechnologies

4:25 p.m. The first personalized adoptive cellular therapy trial using defined multiple targets (ACTolog IMA101-101)
Steffen Walter, PhD – Immatics US


4:35 p.m. A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism
Nicholas Keen, PhD – Bicycle Therapeutics

4:45 p.m. Combining CD27 costimulation and PD-1 blockade into a bispecific antibody improves T cell activation and anti-tumor activity over combination of individual antibodies
Tibor Keler, PhD – Celldex Therapetuics, Inc.

4:55 p.m. no_symbol.pngDevelopment of novel multi-specific compounds for cancer immunotherapy using the DARPin® technology platform
Victor Levitsky, MD, PhD – Molecular Partners AG

5:05  p.m. The uniqueness and persistence of clonal profiles associated with response in study C-144-01 following treatment with lifileucel (LN-144) supports using a polyclonal product to treat solid tumors
Viktoria Gontcharova, PhD – Iovance Biotherapeutics

5:15 p.m. Break

Session 3: Clinical Applications of Multi-Targeted Therapeutic Platforms
5:30 p.m. Clinical Trial Designs
R. Angelo De Claro, MD – Food and Drug Administration

5:50 p.m.

no_symbol.pngCompare and Contrast with Cellular Therapies Panel Discussion
Panelists:
R. Angelo De Claro, MD – Food and Drug Administration
Steffen Walter, PhD – Immatics US
Victor Levitsky, MD, PhD – Molecular Partners AG
Tibor Keler, PhD – Celldex Therapetuics, Inc.
Francesco M. Marincola, MD – Refuge Biotechnologies
Nicholas Keen, PhD – Bicycle Therapeutics
Marcela V. Maus, MD, PhD – Massachusetts General Hospital

6:25 p.m. Closing


Thursday, Nov. 7, 2019
Primer on Tumor Immunology and Cancer Immunotherapy™
Time:
Location:

8:00 a.m. - 5:00 p.m.
Potomac Ballroom AB

Primer Session 1: Tumor Immunity I

8:00 a.m.

Introduction
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

8:05 a.m.

The Adaptive Immune Response
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

8:35 a.m.

Macrophages, Dendritic and Myeloid Cells
Tyler Curiel, MD – UT Health San Antonio

9:05 a.m.

Harnessing Natural Killer Cells and Innate Lymphoid Cells to Potentiate Antitumor Immunity
Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai

9:35 a.m.

Tumor Immunity I Panel Discussion
Moderator:
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

Panelists:

Tyler Curiel, MD – UT Health San Antonio
Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

9:55 a.m.

Break

Primer Session 2: Tumor Immunity II

10:10 a.m.

Regulation of Cancer Immunity by Metabolic and Microbiome Interactions
Greg Delgoffe, PhD – University of Pittsburgh

10:40 a.m.

Redefining Cancer Vaccination
Tanja de Gruijl, PhD – VU University Medical Center

11:10 a.m.

Monoclonal Antibodies and Their Derivatives
Charles G. Drake, MD, PhD – Columbia University

11:40 a.m.

Tumor Immunity II Panel Discussion
Moderator:
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine


Panelists:
Tanja de Gruijl, PhD – VU University Medical Center
Greg Delgoffe, PhD – University of Pittsburgh
Charles G. Drake, MD, PhD – Columbia University

12:00 p.m.

Lunch

Sponsored Symposia
Time:
Location:

11:30 a.m. – 1:00 p.m.
Riverview Ballroom B 4-5

11:30 a.m. Registration and Lunch
12:00 p.m. Immunotherapy in Urothelial Bladder Cancer: Current Treatments and Emerging Research
Clinical Care Options, LLC.

Primer Session 3: Analysis of Resistance and Response

1:00 p.m.

Introduction
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

1:05 p.m.

Extrinsic Mechanisms of Resistance: A Miserable Microenvironment
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

1:35 p.m.

Checkpoint Receptors - Pathways to Resistance
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

2:05 p.m.

Biomarkers of Response to Immunotherapy
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai

2:35 p.m.

no_symbol.pngAnalysis of Resistance and Response Panel Discussion
Moderator
:
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

Panelists:
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai

2:55 p.m.

Break

Primer Session 4: Current IO Immunotherapy

3:10 p.m.

Adoptive T Cell Therapy
Patrick Hwu, MD – University of Texas MD Anderson Cancer Center

3:40 p.m.

Combination Immunotherapies
Leisha Emens, MD, PhD – University of Pittsburgh

4:10 p.m.

Diagnosis, Management and Mechanisms of Immune-related Adverse Events
Jarushka Naidoo, M.B.B.Ch – Johns Hopkins Medicine

4:40 p.m.

Current IO Immunotherapy Panel Discussion
Moderator:
Michael A. Curran, PhD The University of Texas MD Anderson Cancer Center

Panelists:

Leisha Emens, MD, PhD – University of Pittsburgh
Patrick Hwu, MD – University of Texas MD Anderson Cancer Center
Jarushka Naidoo, M.B.B.Ch – Johns Hopkins Medicine

4:55 p.m.

Closing

5:00 p.m.

Adjourn

Workshop on Intratumoral Immunomodulation
Time:
Location:
8:00 a.m. 5:00 p.m.
Cherry Blossom Ballroom

Workshop Session 1: Introduction to Intratumoral Immunomodulation
8:00 a.m.

Introduction
Adi Diab, MD – University of Texas MD Anderson Cancer Center

8:05 a.m.

Background and Introduction to Intratumoral Therapy
Aurélien Marabelle, MD, PhD – Gustave Roussy 

8:35 a.m.

Cold vs. Hot Tumors
Razvan Cristescu, PhD - Merck

8:55 a.m.

Clinical Assessment of Intratumoral Immunomodulation
Jianda Yuan, MD, PhD – Merck Research Laboratories

Workshop Session 2: Modes of Delivery
9:15 a.m.

Intratumoral Immunotherapies from an Interventional Radiology Perspective
Rahul Sheth, MD – The University of Texas MD Anderson Cancer Center

9:35 a.m.

no_symbol.pngAttracting Dendritic Cells to the Tumor with Focal Radiotherapy 
Sandra Demaria, MD – Weill Cornell Medicine

9:55 a.m.

SBRT and Immune Activation
Silvia Formenti, MD – New York-Presbyterian/Weill Cornell Medical Center

10:15 a.m.

Break

Workshop Session 3: Intratumoral Synthetic Modulators
10:40 a.m.

Hot is Not Enough: In Situ Vaccination to Turn Cold Tumors Hot, and Cross-Priming
Joshua Brody, MD – Icahn School of Medicine at Mount Sinai

11:00 a.m.

TLR9
Adi Diab, MD – University of Texas MD Anderson Cancer Center

11:20 a.m

TLR7/8 Agonists in Immuno-Oncology
Willem W. Overwijk, PhD – Nektar Therapeutics

11:40 a.m.

STING at a Crossroads: Untapped Potential for Innate Immunity
Thomas W. Dubensky, PhD – Tempest Therapeutics

12:00 p.m.

Lunch

Workshop Session 4: Intratumoral Oncolytic Modulators
1:00 p.m.

The Role of T-VEC and Other Oncolytic Viruses in Priming the Tumor Microenvironment for Immunotherapy
Howard L. Kaufman, MD, FACS – Replimune Group Inc.

1:20 p.m.

no_symbol.pngIntratumoral Oncolytic Immunotherapy: Is Lysis Really Necessary?
Dmitry Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

1:40 p.m.

Development of Multiplex Oncolytic Viruses
John Bell, PhD – University of Ottawa

Workshop Session 5: Systemic Combinations

2:00 p.m.

Intratumoral Checkpoint Blockade Inhibition
Craig L. Slingluff, MD – University of Virginia

2:20 p.m.

Anti-Tumor Vaccines Platforms
Esteban Celis, MD, PhD – Augusta University

2:40 p.m.

Break

3:00 p.m.

CD40: A Target for Systemic Immune Modulation
Michael Yellin, MD – Celldex Therapeutics, Inc.

3:20 p.m.

no_symbol.pngModulating the Tumor Microenvironment
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai

3:40 p.m.

Regulatory Implications for Drug Development
Maitreyee Hazarika, MD – U.S. Food and Drug Administration

4:00 p.m.

no_symbol.pngSystemic Combinations Panel Discussion
Moderators:
Adi Diab, MD – University of Texas MD Anderson Cancer Center
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai

Panelists:
Esteban Celis, MD, PhD – Augusta University
Jason Luke, MD, FACP – University of Pittsburgh Medical Center
Craig L. Slingluff, MD – University of Virginia
Michael Yellin, MD – Celldex Therapeutics, Inc.
Jianda Yuan, MD, PhD – Merck Research Laboratories

4:55 p.m.

no_symbol.pngClosing
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai

5:00 p.m.

Adjourn

Meet-the-Expert Lunch
Time:
Location:
12:00 p.m. – 1:00 p.m.
National Harbor 4-5
12:00 p.m. Introduction/Welcome from ECS Committee
12:05 p.m.

Table 1:
Basic-Translational Research in Immunology
        

Ana Wu, PhD – City of Hope

Table 2:

Basic-Translational Research in Immunology        
Zihai Li, MD, PhD – The Ohio State University

Table 3:

Clinical-Translational Research in Immunology with Focus on Medical Students and Medical Residents            
Joshua Brody, MD – Icahn School of Medicine at Mount Sinai

Table 4:

Clinical-Translational Research in Immunology with Focus on Fellows and Early Career Clinicians              
David McDermott, MD – Beth Israel Deaconess Medical Center

Table 5:

Partnering and Collaborating with Industry            
Lazslo Radvanyi, PhD – Ontario Institute for Cancer Research

Table 6:

Gaining a Network and Leveraging Support           
Tullia Bruno, PhD – University of Pittsburgh

Table 7:

Career Path: The Big Pharma Industry Perspective             
Edward Cha, MD, PhD – Genentech

Table 8:

Career Path: The Small Biotech Industry Perspective          
Thomas Dubensky, PhD – Tempest Therapeutics

Annual Meeting Session 100: Lessons and Challenges from the Immunotherapy of Hematologic Malignancies: Informing the Next Generation of Cancer Immunotherapies
Organized in collaboration with the American Society of Hematology (ASH)

Time:
Location:
Co-Chairs:
1:00 5:00 p.m.
Potomac Ballroom CD
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
John M. Timmerman, MD – University of California, Los Angeles

1:00 p.m.

Annual Meeting Welcome
Sandra Demaria, MD – Weill Cornell Medicine

1:05 p.m.

no_symbol.pngEnhancing Myeloid cell Functionality in Tumor Lesions
Miriam Merad, MD, PhD  – Icahn School of Medicine at Mount Sinai

1:30 p.m.

Lessons and Challenges from the Immunotherapy of Lymphoma
Stephen Ansell, MD, PhD – Mayo Clinic

1:55 p.m. no_symbol.png(O79) Mapping the spatial architecture of acute myeloid leukemia in the bone marrow microenvironment by multiplexed ion beam imaging
Xavier Rovira-Clave, PhD – Stanford University

2:10 p.m. (O3) Immune infiltration correlates with TP53 mutational status in a multi-cohort acute myeloid leukemia study
Sergio Rutella, MD, PhD, FRCPath – Nottingham Trent University

2:25 p.m. no_symbol.png(O71) AMV564, a novel bivalent, bispecific T-cell engager, targets myeloid-derived suppressor cells
Victoria Smith, PhD – Amphivena Therapeutics, Inc.

2:40 p.m. (O43) Immune profiling of the tumor microenvironment in classic Hodgkin lymphoma using high-complexity mass cytometry is feasible and reveals significant multi-compartment heterogeneity between patients
El-ad David Amir, PhD – Astrolabe Diagnostics, Inc.

2:55 p.m. Break
3:10 p.m.

Current State of the Art in CAR cell Therapy
Marcela Maus, MD, PhD – Massachusetts General Hospital

3:35 p.m.

Addressing Relapse After CAR T cell Therapy for B cell Malignancies
Terry Fry, MD – University of Colorado School of Medicine, Children's Hospital Colorado

4:00 p.m. (O25) Dominant negative PD1 armored CAR T cells induce remission in relapsed or refractory non-hodgkin lymphoma (NHL) patients
Victor Lu, PhD – Innovative Cellular Therapeutics

4:15 p.m. no_symbol.png(O7) P-BCMA-ALLO1 — a nonviral, allogeneic anti-BCMA CAR T therapy with potent antit-tumor function for the treatment of multiple myeloma
Maximilian Richter, PhD – Poseida Therapeutics

4:30 p.m. (O9) Enhancing affinity of CD22-directed CAR T cells increases activation signaling and in vivo response to CD22lo leukemia
Zachary Walsh, BA – Children's Hospital Colorado

4:45 p.m. no_symbol.png(O61) Myeloid cell-targeted miR-146a mimic alleviates NF-κB-driven cytokine storm without interfering with CD19-specific CAR T cell activity against B cell lymphoma
Marcin Kortylewski, PhD – City of Hope

Poster Symposium
Time:
Location:
Co-Chairs:
5:30 7:30 p.m.
Potomac Ballroom CD
Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Institute
Roberta Zappasodi, PhD - Memorial Sloan Kettering Institute

5:30 p.m. no_symbol.png(O54) Germline genetic variation affects the immune response in cancer
Rosalyn Sayaman, PhD – City of Hope Comprehensive Cancer Center

5:40 p.m. (O52) ADT-mediated IL-8 Promotes Myeloid Infiltration and Prostate Cancer Progression
Zoila Lopez Bujanda, MS – Columbia University

5:50 p.m. no_symbol.png(O76) Interferon-Gamma mediated T cell exhaustion generates distinct tumor microenvironments in synchronous melanoma via PD-1/PD-L1 axis
Shuyang Qin, BS – University of Rochester School of Medicine and Dentistry

6:00 p.m. (O60) Tumor cell-intrinsic defects in STING pathway signaling and IFN-β gene regulation
Blake Flood, BS – University of Chicago

6:10 p.m. (O39) Soluble TNFα induced mucin 4 is a mediator of trastuzumab resistance and of an immunosuppressive tumor microenvironment in HER2+ breast cancer
Sofia Bruni, MS – Instituto de Biologia y Medicina Experimental - CONICET

6:20 p.m. no_symbol.pngQuestion & Answer
6:30 p.m. (O38) A single-dose immunotherapy that remodels the tumor microenvironment for subsequent curative responses to checkpoint blockade
Chensu Wang, PhD  Massachusetts Institute of Technology

6:40 p.m. (O37) PD1 blockade augments adoptive T cell therapy via endogenous T cells rather than direct enhancement of transferred T cells
John Davies, PhD – National Institutes of Health, National Cancer Institute


6:50 p.m. (O72) Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers
Fan Zhang, PhD – Fred Hutchinson Cancer Research Center


7:00 p.m. no_symbol.png(O14) Immune selection for IFN-g signaling mutant cancer cells involves tumor heterogeneity and clonal cooperation
Shuyin Li, PhD – University of Chicago

7:10 p.m. (O58) Human tumor-infiltrating MAIT cells display hallmarks of antigen-recognition that are associated with tumor bacterial infiltration
Shamin Li, PhD – Fred Hutchinson Cancer Research Center


7:20 p.m. no_symbol.pngQuestion & Answer


Grant Writing Workshop
Time:
Location:

6:00 8:00 p.m.
National Harbor 10-11

Session I: Overview of Grant Writing

6:00 p.m.
Welcome
Claire I. Vanpouille-Box, PhD – Weill Cornell Medicine

6:05 p.m.

Overview of Grant Opportunities
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute

6:15 p.m.

Principles of Grant Writing
Thomas Gajewski, MD, PhD – University of Chicago

6:35 p.m.

Panel Discussion
Moderator:
Saman Maleki, PhD – Western University

Panelists:
Thomas Gajewski, MD, PhD – University of Chicago
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute

Session II: You Submitted Your Grant: Now What Happens?

6:45 p.m.

Attendee Review of Specific Aims Document

6:50 p.m.

A Look Inside a Study Section
Denise R. Shaw, PhD – National Institutes of Health

6:55 p.m.

no_symbol.pngMock Study Session
Moderator:
David Aggen, MD, PhD – Memorial Sloan Kettering Cancer Center

Panelists:
Ana Anderson, PhD – Harvard Medical School – Secondary Reviewer
Thomas Gajewski, MD, PhD – University of Chicago – Chair
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute –                  Primary Reviewer
Marco Ruella, MD – University of Pennsylvania – Reader
Denise R. Shaw, PhD – National Institutes of Health – Scientific Review Officer
Claire I. Vanpouille-Box, PhD – Weill Cornell Medicine – Third Reviewer

7:10 p.m.

Attendee Review of Summary Statement Document

7:15 p.m.

What Happens After Reviews are Conducted/How to Revise Your Grant
Malgorzata Klauzinska, PhD – National Institutes of Health

7:30 p.m.

no_symbol.pngPanel Discussion
Moderator:
David Aggen, MD, PhD – Memorial Sloan Kettering Cancer Center

Panelists:
Ana Anderson, PhD – Harvard Medical School
Thomas Gajewski, MD, PhD – University of Chicago
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute
Marco Ruella, MD – University of Pennsylvania
Denise R. Shaw, PhD – National Institutes of Health
Claire I. Vanpouille-Box, PhD – Weill Cornell Medicine

7:55 p.m.

Closing Remarks
Saman Maleki, PhD – Western University


Friday, Nov. 8, 2019
Presidential Breakfast & Membership Business Meeting
Time:                                  7:00 7:45 a.m.
Location:                            Cherry Blossom Ballroom

Session 200:
National Cancer Institute Update

Time:
Location:

7:55 8:35 a.m.
Potomac Ballroom

7:55 a.m.

2018 NCI Immunotherapy Fellowship
Jason M. Redman, MD – National Cancer Institute

8:00 a.m.

2017 NCI Immunotherapy Fellowship
Ariel E. Marciscano, MD – Memorial Sloan Kettering Cancer Center


8:05 a.m.

Cancer Immunotherapy Trials Network Update
Martin A. Cheever, MD – Fred Hutchinson Cancer Research Center

8:20 a.m.

Immuno-Oncology Translational Network Update
Kevin Howcroft, PhD  – National Cancer Institute

Session 201: Richard V. Smalley, MD Memorial Lectureship

Time:
Location:
Chair:

8:35 – 9:25 a.m.
Potomac Ballroom
Mario Sznol, MD – Yale School of Medicine

8:35 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

8:40 a.m. no_symbol.pngTraveling the Cancer Vaccine Road and Reaching My Destination
Olivera J. Finn, PhD – University of Pittsburgh School of Medicine
9:20 a.m.

no_symbol.pngQuestion & Answer
Olivera J. Finn, PhD – University of Pittsburgh School of Medicine

Session 202: Autoimmunity, Toxicity, and Cancer Immunotherapy

Time:
Location:
Co-Chairs:

9:25 a.m. 12:00 p.m.
Potomac Ballroom
Jarushka Naidoo, MD – Johns Hopkins Sidney Kimmel Cancer Center
Virginia Pascual, MD – Weill Cornell Medicine

9:25 a.m.

Introduction
Jarushka Naidoo, MD – Johns Hopkins Sidney Kimmel Cancer Center

9:30 a.m.

Clinical irAE
Jarushka Naidoo, MD – Johns Hopkins Sidney Kimmel Cancer Center

9:50 a.m.

Basic Mechanisms in Autoimmunity/ Novel, New Data on T cells
Virginia Pascual, MD – Weill Cornell Medicine

10:10 a.m.

Checkpoint Blockade and Immune Homeostasis in the Gastrointestinal Tract
Michael L. Dougan, MD, PhD – Massachusetts General Hospital

10:30 a.m.

Break

10:50 a.m.

no_symbol.png(O63) Gastric toxicity associated with PD-1 blockade therapy revealed by Multiplexed Ion Beam Imaging
Selena Ferrian, PhD – Stanford University

11:05 a.m.

(O4) Preclinical CAR-T cell target safety, biodistribution, and tumor infiltration analysis using in situ hybridization technology
Courtney M. Anderson, PhD – Advanced Cell Diagnostics, Inc.

11:20 p.m.

no_symbol.png(O11) Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
Shuming Chen, PhD – Johns Hopkins University School of Medicine

11:35 a.m.

no_symbol.pngPanel Discussion
Moderators:
Jarushka Naidoo, MD – Johns Hopkins Sidney Kimmel Cancer Center

Virginia Pascual, MD – Weill Cornell Medicine

Panelists:
Michael L. Dougan, MD, PhD – Massachusetts General Hospital


Session 203: Late-Breaking Abstract Session
Time:
Location:
Chair:
12:00 p.m. 12:30 p.m.
Potomac Ballroom
Ana Carrizosa Anderson, PhD – Harvard Medical School

12:00 p.m. (O83) Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
Ronnie Shapira-Frommer, MD – Oncology Institute, Sheba Medical Center, Ramat-Gan, Israel

12:15 p.m. (O85) Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a Toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab
John M. Kirkwood, MD – University of Pittsburgh Medical Center

Lunch, Exhibits and Poster Viewing
Time:
Location:
12:30 2:00 p.m.
Prince George's Exhibition Halls AB
Odd Numbered Posters Presented


Sponsored Symposia
Time:
Location:

12:15 – 1:45 p.m.
Riverview Ballroom A3

12:15 p.m. Registration and Lunch
12:45 p.m. Increasing Survival in Stage III NSCLC: Optimizing Care and Addressing New Clinical Challenges
Clinical Care Options, LLC.

Time:
Location:

12:30 – 1:45 p.m.
Riverview Ballroom B 4-5

12:30 p.m. Registration and Lunch
12:45 p.m. Role of Immunotherapy in Endometrial and Cervical Cancers
Medscape


Concurrent Rapid Oral Abstract Presentations - Basic Research
Time:
Location:
Co-Chairs:
12:45 1:45 p.m.
National Harbor 10-11

Ravi Patel, MD, PhD – University of Wisconsin-Madison
Yared Hailemichael, PhD – The University of Texas MD Anderson Cancer Center

1:45 p.m.
(O62)Targeting myeloid tumors by Off-the-Shelf NK cells using an NKG2C-IL15-CD33 Trispecific Killer Engager
Emily Chiu, BA – University of Minnesota

12:53 p.m. (O59) CD8 T-cell infiltration into renal tumors requires a supportive antigen presenting niche and is independent of PD-L1 status
Caroline S. Jansen, BS – Emory University

1:01 p.m. (O53) Altered T-cell clonotype composition is strongly associated with differential functional orientation of colon cancer microenvironment
Jessica Roelands – Sidra Medical Research Center

1:09 p.m. Question & Answer
Emily Chiu, BA – University of Minnesota
Caroline S. Jensen, BS – Emory University
Jessica Roelands – Sidra Medical Research Center


1:15 p.m. no_symbol.pngInhibition of autophagy enhances multifunctional genetically-engineered NK cell-based immunotherapy of glioblastoma
Jiao Wang, PhD – Purdue University


1:23 p.m. no_symbol.png(O55) Antigen-cross presentation promotes the development of terminally differentiated CD8 T cells in young individuals
Ardiana Moustaki, PhD – St. Jude Children's Research Hospital

1:31 p.m. no_symbol.png(O15) Replication stress response defects predict response to immune checkpoint blockade across multiple cancer lineages
Daniel McGrail, PhD – The University of Texas MD Anderson Cancer Center

1:39 p.m. no_symbol.pngQuestion & Answer
Jiao Wang, PhD – Purdue University

Ardiana Moustaki, PhD – St. Jude Children's Research Hospital
Daniel McGrail, PhD – The University of Texas MD Anderson Cancer Center

Concurrent Rapid Oral Abstract Presentations - Clinical
Time:
Location:
Co-Chairs:
12:45 1:45 p.m.
Cherry Blossom Ballroom
Lorenzo Falchi, MD  Memorial Sloan Kettering Cancer Center
Helen K. Angell, PhD – AstraZeneca

12:45 p.m.
(O68) Characteristics of the microbiome form and function of complete responders to Anti-PD1 and healthy individuals implicate donor selection for clinical trial design
Md Abdul Wadud Khan, PhD – The University of Texas MD Anderson Cancer Center

12:53 p.m. no_symbol.png(O12) B-cells activated by checkpoint blockade immunotherapy and radiation improve overall survival in squamous cell carcinomas
Sangwoo Kim, BA – University of California, San Diego

1:01 p.m. (O77) Clinicopathological and genomic correlates of PD-L1 expression in nonsquamous non-small cell lung cancer
Giuseppe Lamberti, MD – Dana-Farber Cancer Institute

1:09 p.m. no_symbol.pngQuestion & Answer
Md Abdul Wadud Khan, PhD – The University of Texas MD Anderson Cancer Center
Sangwoo Kim, BA – University of California, San Diego
Giuseppe Lamberti, MD – Dana-Farber Cancer Institute

1:15 p.m. no_symbol.png(O67) Variation in the commensal urinary microbiome is associated with response to Bacillus Calmette-Guérin (BCG) immunotherapy in early stage urothelial bladder cancer
Randy F. Sweis, MD – University of Chicago

1:23 p.m. Analysis of H&E Images Using Deep Learning for the Prediction of Distant Metastic Recurrence in Early Stage Melanoma
Yvonne Saenger, MD – Columbia University Medical Center

1:31 p.m. no_symbol.png(O46) Characterization of tumor infiltrating and post HSCT NK and T cells in human cancer patients
Sean Judge, MD, MS – University of California, Davis

1:39 p.m. no_symbol.pngQuestion & Answer
Randy F. Sweis, MD – University of Chicago
Sean Judge, MD, MS – University of California, Davis

Session 204: Immune Checkpoints: Newer Targets and Update on Combinations
Time:
Location:
Co-Chairs:
2:00 4:20 p.m.
Potomac Ballroom
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and
Research Institute

2:00 p.m. Introduction
2:05 p.m. Targeting CD38 to optimize PD-1/PD-L1 and CTLA-4 Blockade Immunotherapy
Don L. Gibbons, MD, PhD – The University of Texas MD Anderson Cancer Center

2:25 p.m.

Combinations: IL-2
Michael Hurwitz, MD, PhD – University of Texas MD Anderson Cancer Center

2:45 p.m. The Emerging Role of TLR Agonists in Cancer Immunotherapy
Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and
Research Institute

3:05 p.m.

no_symbol.pngNovel Targets: TIM-3
Hassane M. Zarour, MD – UPMC Hillman Cancer Center

3:25 p.m. Immune Contexture and Immune Escape at Pre-Cancer Lesion Stages
Jérôme Galon, PhD – INSERM, Sorbonne Universites Paris

3:45 p.m. (O40) Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers
Jason Luke, MD, FACP – University of Pittsburgh Medical Center

4:00 p.m. no_symbol.pngPanel Discussion
Moderators:
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and
Research Institute

Panelists
Jérôme Galon, PhD – INSERM, Sorbonne Universites Paris
Don L. Gibbons, MD, PhD – The University of Texas MD Anderson Cancer Center
Jason Luke, MD, FACP – University of Pittsburgh Medical Center
Hassane M. Zarour, MD – UPMC Hillman Cancer Center

4:15 p.m. Closing

Concurrent Session 205: Biology of T cells
Time:
Location:
Co-Chairs
4:50 6:15 p.m.
Potomac Ballroom CD
Rafi Ahmed, PhD – Emory University
Ana Carrizosa Anderson, PhD – Harvard Medical School

4:50 p.m. no_symbol.pngInTOXication Causes T-cell Exhaustion in Chronic Infection
Dietmar Zehn, PhD, MD – Technical University of Munich
5:15 p.m. no_symbol.pngSingle Cell Profiling of Anti-Tumor T cell Response
Enrico Lugli, PhD – Instituto Clinico Humanitas IRCCS
5:40 p.m. Biology of T cells
Anjana Rao, PhD – La Jolla Institute for Immunology

6:05 p.m. no_symbol.pngO49) Chronic activation under hypoxia drives T cell differentiation to exhaustion
Nicole E. Scharping, PhD –  University of Pittsburgh

Concurrent Session 206: High Impact Clinical Trials
Time:
Location:
Co-Chairs:
4:50 6:15 p.m.
Prince George's Exhibition Hall C
Jeffrey Weber, MD, PhD – NYU Langone Medical Center
Roy Herbst, MD, PhD – Yale Cancer Center

4:50 p.m. Introduction
Roy Herbst, MD, PhD – Yale Cancer Center

4:55 p.m. (O29) Phase I study of multisite stereotactic body radiotherapy plus nivolumab and urelumab or nivolumab and cabiralizumab in patients with advanced solid tumors
Corey C. Foster, MD, MS – The University of Chicago Medicine

5:10 p.m. (O26) A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis
Matthew G. Krebs, MD, PhD –The University of Manchester

5:25 p.m. (O27) Clinical response to tumor infiltrating lymphocytes (TIL) in stage 4 non-small cell lung cancer (NSCLC) correlates with neoantigen-specificity: A phase I trial
Chao Wang, PhD – Moffitt Cancer Center

5:40 p.m. no_symbol.png(O18) Neoantigen vaccination targeting shared epidermal growth factor receptor (EGFR) mutations induces clinical and immunological responses in non-small cell lung cancer patients
Gregory A. Lizee, PhD – The University of Texas MD Anderson Cancer Center

5:55 p.m. (O21) Safety and clinical activity of avelumab (MSB0010718C), an anti-programed death-ligand 1 (PD-L1) antibody, in recurrent thymic epithelial tumors (TETs)
Arun Rajan, MD – National Cancer Institute

6:10 p.m. Closing
Jeffrey Weber, MD, PhD – NYU Langone Medical Center

Concurrent Session 207: Harnessing Antigen-Presenting cells to Boost Anti-Tumor Immunity
Time:
Location:
Co-Chairs:
4:50 6:15 p.m.
Potomac Ballroom AB
Matthew Krummel, PhD – University of California, San Francisco
Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

4:50 p.m.

no_symbol.pngTumor-Resident DC Impact Anti-Tumor T cell Responses
Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

5:10 p.m.

no_symbol.pngPhagocytic cells, Migratory cells, and Human Studies
Matthew Krummel, PhD – University of California, San Francisco

5:30 p.m. no_symbol.pngBasic Biology of Regulation of the cell Biology of Antigen Cross-Presentation by Dendritic cells
Julie Magarian Blander, PhD – Weill Cornell Medicine

5:50 p.m. no_symbol.png(O44) Intratumoral CD163+ DC amplify the type 1 immune response of CD4+CD161+ T cells in HPV16-associated cancers and are associated with better survival
Chantal Duurland, PhD – Leiden University Medical Center

6:00 p.m. (O57) Novel dsRNA-sensing dendritic cells enhance anti-tumor immunity
Ellen Duong, ScB – MIT

6:10 p.m. no_symbol.pngAbstract Question and Answer
Chantal Duurland, PhD – Leiden University Medical Center
Ellen Duong, ScB – MIT

Concurrent Session 208: Tumor Cell Atlas Efforts Big Data
Time:
Location:
Chair:
4:50 6:15 p.m.
Cherry Blossom Ballroom
Orit Rozenblatt-Rosen, PhD – Broad Institute

4:50 p.m. no_symbol.pngInflammatory Microenvironment in Breast Cancer Brain Metastasis
Devon A. Lawson, PhD – University of California, Irvine

5:10 p.m. Glioma
Mario Suva, MD, PhD  Harvard Medical School, Massachusetts General Hospital

5:30 p.m. no_symbol.pngHighplex Profiling of Microsatellite Stable and Instable Human Colorectal Carcinoma
Karin Pelka, PhD – Broad Institute of MIT and Harvard

5:50 p.m. no_symbol.png(O80) Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors
Andrew Gentles, PhD – Stanford University

6:00 p.m. (O42) Transcriptional dissection reveals antitumor role of T follicular helper cells in head and neck cancer
Anthony R. Cillo, PhD – University of Pittsburgh

6:10 p.m. no_symbol.pngQuestion & Answer
Andrew Gentles, PhD – Stanford University
Anthony R. Cillo, PhD – University of Pittsburgh

Concurrent Session 209: Virus Driven Cancers
Time:
Location:
Co-Chairs:

4:50 6:15 p.m.
National Harbor 10-11
Robert Ferris, MD, PhD – UPMC Hillman Cancer Center
Weijing Sun, MD, FACP – University of Kansas Medical Center

4:50 p.m.

HPV and Head and Neck Cancers
Robert Ferris, MD, PhD – UPMC Hillman Cancer Center

5:05 p.m.

EBV and Cancers
Cliona M. Rooney, PhD – Baylor College of Medicine

5:20 p.m.

Liver Cancer
Jody C. Olson, MD, FACP – University of Kansas Medical Center

5:35 p.m.

Merkel Cell Carcinoma
Suzanne L. Topalian, MD – Johns Hopkins University School of Medicine

5:50 p.m.

(O19) Final results from a phase 2 study using off-the-shelf activated natural killer (aNK) cells in combination with N-803, an IL-15 superagonist, in patients with metastatic Merkel cell carcinoma (MCC)
Shailender Bhatia, MD – University of Washington

6:00 p.m.

(O17) A novel enantio-specific cationic lipid R-DOTAP + HPV16 E6 & E7 antigens induces potent antigen-specific CD8+ T cell responses in-vivo in subjects with CIN and high-risk human papillomavirus infection
Lauren V. Wood, MD – PDS Biotechnology

6:10 p.m. Question & Answer
Shailender Bhatia, MD – University of Washington
Lauren V. Wood, MD – PDS Biotechnology

Poster Reception
Time:
Location:
6:30 – 8:00 p.m.
Prince George's Exhibition Halls AB

Sponsored Symposia
Time:
Location:

6:30 - 8:00 p.m.
Riverview Ballroom B 4-5

6:30 p.m. High-Plex Spatial Analysis of the Tumor Microenvironment: Advancements and Applications
Akoya Biosciences, Inc.


Career Connections Networking Reception
Time:
Location:
8:15  9:30 p.m.
Potomac Ballroom Foyer


Saturday, Nov. 9, 2019

Point-Counterpoint: New Data and Controversies on Immunotherapy Combinations in the First-Line Treatment of NSCLC

Time:
Location:
7:00 - 7:45 a.m.
Cherry Blossom Ballroom
7:00 a.m. Single Agents
Naiyer A. Rizvi, MD – Columbia University Medical Center

7:10 a.m. IO-IO Combinations
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

7:20 a.m. IO-chemotherapy Combinations
Roy Herbst, MD, PhD – Yale Cancer Center

7:30 a.m. Panel Discussion
Moderators:
Jedd D. Wolchok, MD, PhD  Memorial Sloan Kettering Cancer Center
Mario Sznol, MD Yale Cancer Center

Panelists:
Naiyer A. Rizvi, MD – Columbia University Medical Center
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Roy Herbst, MD, PhD – Yale Cancer Center


7:50 a.m.

no_symbol.pngOrganizer Welcome
Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

Session 300: SITC Initiatives Update

Time:
Location:

7:55 8:40 a.m.
Potomac Ballroom

7:55 a.m.

SITC Anti-PD-1/PD-L1 Resistance Taskforce Update
Ryan J. Sullivan, MD – Massachusetts General Hospital

8:10 a.m. SITC Policy Committee Update
George J. Weiner, MD – University of Iowa

Session 301: Friends of Cancer Research Update

Time:
Location:

8:40 – 8:55 a.m.
Potomac Ballroom

8:40 a.m.

TMB Harmonization Project Update
Jeff Allen, PhD - Friends of Cancer Research

Session 302: Keynote Address

Time:
Location:
Chair:

8:55 9:45 a.m.
Potomac Ballroom
Mario Sznol, MD – Yale School of Medicine

8:55 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9:00 a.m.

no_symbol.pngUsing Advanced Multiplex Optical Imaging Methods to Study the Tumor Micro-environment and Response to Cancer Immunotherapy
Ronald N. Germain, MD, PhD – NIAID, NIH

9:40 a.m.

no_symbol.pngQuestion & Answer
Ronald N. Germain, MD, PhD – NIAID, NIH

Session 303: Imaging Technologies

Time:
Location:
Co-Chairs:
9:45 11:50 a.m.
Potomac Ballroom
Carlo Bifulco, MD – Providence Portland Medical Center
Michael Dustin, PhD – The Kennedy Institute of Rheumatology


9:45 a.m.

Introduction
Carlo Bifulco, MD – Providence Portland Medical Center

9:50 a.m.

no_symbol.pngSuper-Resolution Imaging
Michael Dustin, PhD – The Kennedy Institute of Rheumatology

10:05 a.m.

no_symbol.pngIO Neoadjuvant Response Assessment by mIHCm
Janis Taube, MD, MSc – Johns Hopkins Medicine

10:20 a.m.

Multiplexed Imaging of Tissues- MIBI or CODEX
Michael Angelo, MD, PhD – Stanford Medicine

10:35 a.m.

Break

10:50 a.m.

Integrating Single-cell RNA-Seq with Spatial Transcriptomics in Pancreatic Ductal Adenocarcinoma
Itai Yanai, PhD – NYU School of Medicine

11:05 a.m.

ImmunoPET for Whole Body Imaging of Immune Cell Subsets
Anna M. Wu, PhD – University of California, Los Angeles

11:20 a.m.

no_symbol.pngReal-Time Insights into the Innate Immune Reaction Against Early Stage Glioblastomas
Dorian McGavern, PhD – National Institutes of Health

11:35 a.m.

(O1) Flexible Copper-64-nanoparticle-based cell labeling system allows for in vivo tracking of adoptively transferred T-cells by PET/CT
Hólmfridur R. Halldórsdóttir, MSc – Technical University of Denmark

Session 304: Late-Breaking Abstract Session

Time:
Location:
Chair:

11:50 a.m. 12:20 p.m.
Potomac Ballroom
Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and
Research Institute

11:50 a.m.

(O82) A phase 1 dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
Geoffrey Ku, MD – Memorial Sloan Kettering Cancer Center

12:05 p.m.

(O81) IMpower110: Interim overall survival (OS) analysis of a Phase III study of atezolizumab (atezo) monotherapy vs platinum-based chemotherapy (chemo) as first-line (1L) treatment in PD-L1–selected NSCLC
Giuseppe Giaccone, MD, PhD – Weil Cornell Medicine

Session 305: SITC Sparkathon 2018 (SITCure): When is it Safe to Stop Immunotherapy? A Randomized Trial of Early Cessation of Immunotherapy in Patients with Melanoma after 6 Months or More of Stable Disease on Nivolumab Maintenance
Time:
Location:

12:20 12:35 p.m.
Potomac Ballroom

12:20 p.m.

SITC Sparkathon 2018 (SITCure): When is it Safe to Stop Immunotherapy? A Randomized Trial of Early Cessation of Immunotherapy in Patients with Melanoma after 6 Months or More of Stable Disease on Nivolumab Maintenance
Thomas Marron, MD, PhD – Mount Sinai Hospital

Lunch, Exhibits, and Poster Viewing
Time:
Location:

12:50 – 1:50 p.m.
Prince George's Exhibition Halls AB
Even Numbered Posters Presented

Concurrent Rapid Oral Abstract Presentations - Basic Research
Time:
Location:
Co-Chairs:

12:50 – 1:50 p.m.
National Harbor 10-11
Jessica E. Thaxton, PhD – Medical University of South Carolina
Aaron Ring, MD, PhD – Yale School of Medicine

12:50 p.m. no_symbol.png(O69) Helicobacter hepaticus remodels the tumor immune microenvironment and reduces colorectal tumor burden
Abigail E. Overacre-Delgoffe, PhD - University of Pittsburgh

12:58 p.m. (O75) Selective induction of S100a8/a9 heterodimer protein in pancreatic cancer in response to immune selection pressure

Reham Ajina, MS- Georgetown University

1:06 p.m. (O47) IL-35+ B cells regulates anti-tumor immune response in pancreatic cancer
Bhalchandra Mirlekar, PhD - University of North Carolina at Chapel Hill

1:14 p.m. no_symbol.pngQuestion & Answer
Abigail E. Overacre-Delgoffe, PhD - University of Pittsburgh
Reham Ajina, MS- Georgetown University

Bhalchandra Mirlekar, PhD - University of North Carolina at Chapel Hill

1:20 p.m. (O41) Vasoactive intestinal peptide: a novel checkpoint pathway in pancreatic ductal adenocarcinoma
Sruthi Ravindranathan, PhD - Emory University

1:28 p.m. no_symbol.png(O48) Characterizing the anti-tumor immune response to an array of tumor cell lines expressing unique neoantigens
Kim B. Nguyen, BA - Massachusetts Institute of Technology

1:36 p.m. no_symbol.pngTumor-infiltrating regulatory T cell function is metabolically supported through lactate-mediated symbiosis with the tumor microenvironment
McLane Watson, BS – University of Pittsburgh

1:14 p.m.

no_symbol.pngQuestion & Answer
Sruthi Ravindranathan, PhD - Emory University
Kim B. Nguyen, BA - Massachusetts Institute of Technology
Maria Cortez, PhD - The University of Texas MD Anderson Cancer


Concurrent Rapid Oral Abstract Presentations - Clinical
Time:
Location:
Co-Chairs:

12:50 – 1:50 p.m.
Cherry Blossom Ballroom
Grey Wilkinson, PhD Oncolytics Biotech Inc.
Aung Naing, MD – MD Anderson Cancer Center

12:50 p.m. no_symbol.png(O78) Identification of breast cancer neoantigens exposed by radiation therapy
Claire Lhuillier, PhD –  Weill Cornell Medical College

12:58 p.m. (O33) Immune enrichment and functional T-cell receptor (TCR) frequencies predict response to immune checkpoint blockade (ICB) in selected fusion-associated sarcomas
Akash Mitra, BS –  The University of Texas MD Anderson Cancer Center


1:06 p.m. (O10) Licensing of CAR-T cell persistence and function by STING agonist in breast cancer
Nuo Xu, PhD Candidate – University of North Carolina at Chapel Hill

1:14 p.m. no_symbol.pngQuestion & Answer
Claire Lhuillier, PhD –  Weill Cornell Medical College
Akash Mitra, BS –  The University of Texas MD Anderson Cancer Center
Nuo Xu, PhD Candidate – University of North Carolina at Chapel Hill


1:20 p.m. (O2) Combining transcriptomic and tissue-based immune biomarkers to improve recurrence prediction in stage II-III melanoma
Robyn Gartrell, MD  Columbia University/ New York Presbyterian

1:28 p.m. (O70) CD122-selective IL-2 complexes treat ovarian carcinomas, possibly by dysregulating Treg differentiation and reducing suppression, and promoting T cell stem cells
Yilun Deng, MD, PhD  UT Health San Antonio


1:36 p.m. (O73) Designed improvement to T-cell immunotherapy by integrated single cell profiling
Irfan N. Bandey, PhD  University of Houston


1:14 p.m.

Question & Answer
Robyn Gartrell, MD  Columbia University/ New York Presbyterian
Yilun Deng, MD, PhD – UT Health San Antonio
Irfan N. Bandey, PhD – University of Houston

Sponsored Symposia
Time:
Location:

12:35 – 1:35 p.m.
Riverview Ballroom B 4-5

12:35 p.m. Adaptive Biotechnologies’ Immune Medicine Platform — Aiming to transform the diagnosis and treatment of disease
Adaptive Biotechnologies

Time:
Location:

12:35 – 1:35 p.m.
Riverview Ballroom A3

12:35 p.m. Immune Profiling of Clinical Cohort Samples Using Highly Multiplexed Ion Beam Imaging (MIBI) Technology to Characterize Spatial Organization in the Tumor Microenvironment
IONpath, Inc.


Session 306: Presidential Session
Time:
Location:
Chair:

2:05 3:30 p.m.
Potomac Ballroom
Mario Sznol, MD – Yale School of Medicine

2:05 p.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

2:10 p.m.

(O45) Overexpression of CD200 is a stem cell-specific mechanism of T cell evasion in AML
Shelley Herbrich, MS – The University of Texas MD Anderson Cancer Center

2:25 p.m.

no_symbol.png(O56) Expression of ART1, an extracellular mono ADP-ribosylase, promotes lung cancer growth and dissemination by limiting tumor infiltration of P2X7R+ CD8+ T cells and CD103+ dendritic cells
Erik Wennerberg, PhD – Weill Cornell Medicine

2:40 p.m. no_symbol.pngExpert Discussant
Dario A.A. Vignali, PhD – University of Pittsburgh

2:50 p.m. no_symbol.png(O66) Patient-derived microbiota germ-free mouse model for identifying mechanisms of checkpoint blockade efficacy modulation
Vyara Matson, PhD – University of Chicago

3:05 p.m. no_symbol.png(O8) The Thrombospondin-1/CD47 signaling axis serve as potential markers of immune checkpoint blockade response modulating immune cell bioenergetics in the tumor microenvironment
Elizabeth R. Stirling – Wake Forest University

3:20 p.m. Expert Discussant

Madhav V. Dhodapkar, MD – Emory University

Concurrent Session 307: Machine Learning Approaches and Applications
Time:
Location:
Co-Chairs:

3:45 5:00 p.m.
Cherry Blossom Ballroom
Douglas Lauffenburger, PhD – Massachusetts Institute of Technology
Kurt A. Schalper, MD, PhD – Yale School of Medicine

4:15 p.m.

Deep Learning Algorithms
Douglas Lauffenburger, PhD – Massachusetts Institute of Technology

3:45 p.m.

no_symbol.pngClinicopathologic and Molecular Markers to Assess Anti-tumor Immune Responses
Kurt A. Schalper, MD, PhD – Yale School of Medicine

4:00 p.m.

Deciphering Cell-Cell Interactions in the Melanoma TME from Single-cell Profiling Data
Kathryn Miller-Jensen, PhD – Yale University

4:30 p.m. Enhancing Predictors of Neoantigens and TCRs
Marta Łuksza, PhD – Mount Sinai
4:45 p.m. (O65) Artificial intelligence-powered retrospective analysis of PD-L1 expression in nivolumab trials of advanced non-small cell lung cancer
Vipul Baxi, MS – Bristol-Myers Squibb

Concurrent Session 308: Clinical Management
Time:
Location:
Co-Chairs:

3:45 5:00 p.m.
National Harbor 10-11
Marianne Davies, DNP, AOCNP – Yale School of Nursing
Elad Sharon, MD, MPH – National Cancer Institute

3:45 p.m. Response Criteria/ Patient Selection
Nicole Drezner, MD – Food & Drug Administration
4:05 p.m. Management of Patients in a Clinical Setting
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
4:25 p.m.

Combining Toxicity Management Strategies from a Program Perspective
Kerry Reynolds, MD – Massachussets General Hospital

4:45 p.m

(O64) Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
Hamzah Abu-Sbeih, MD – The University of Texas MD Anderson Cancer Center

Concurrent Session 309: Single Agent Phase 1 Clinical Trials
Time:
Location:
Co Chairs:
3:45 5:00 p.m.
Prince George's Exhibition Hall C
Helen Chen, MD – National Cancer Institute 
Naiyer Rizvi, MD – Columbia University Medical Center

3:45 p.m. (O31) Intratumoral INT230-6 injection into solid tumors kills tumors and induces immune cell infiltration leading to abscopal responses and prolonged disease control in multiple refractory cancer types
Jacob Thomas, MD – USC Norris Comprehensive Cancer Center

4:00 p.m. no_symbol.png(O30) A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors
Ben Markman, MBBS FRACP – Monash Medical Centre, Monash Health

4:15 p.m. (O32) Single agent anti-tumor activity in PD-1 refractory NSCLC: phase 1 data from the first-in-human trial of NC318, a Siglec-15-targeted antibody
Anthony W. Tolcher, MD, FRCPC – Next Oncology

4:30 p.m. no_symbol.png(O36) A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors
Ulrike Gnad-Vogt, MD – CureVac AG

4:45 p.m. (O28) First-in-Class Small Molecule CA-170 Targeting VISTA: A Report on Efficacy Outcomes from a Cohort of 12 Malignant Pleural Mesothelioma (MPM) Patients in Study CA-170-101
Marjorie G. Zauderer, MD, MS, FACP – Memorial Sloan Kettering Cancer Center
Break

Concurrent Session 310: Combination Phase 1-2 Clinical Trials

Time:
Location:
Co-Chairs:

5:15 – 6:30 p.m.
Prince George's Exhibition Hall C
Adil Daud, MBBS, MD – University of California, San Francisco
Howard Streicher, MD – National Cancer Institute

5:15 p.m.

(O35) Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study
Adi Diab, MD – The University of Texas MD Anderson Cancer Center

5:30 p.m.

(O20) A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma
Alexander N. Shoushtari, MD – Memorial Sloan Kettering Cancer Center

5:45 p.m.

(O24) Phase II trial of concurrent nivolumab and radiation therapy in chemotherapy ineligible muscle invasive bladder cancer [NUTRA trial NCT03421652]
Ulka N. Vaishampayan, MD – Wayne State University and Barbara Ann Karmanos Cancer Institute

6:00 p.m.

(O16) Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) – Final Results of the phase II AVETUX trial (AIO-KRK-0216)
Alexander Stein, MD – University Cancer Center Hamburg

6:15 p.m.

(O23) Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI)
Pavlos Msaouel, MD, PhD – The University of Texas MD Anderson Cancer Center

Concurrent Session 311: A Tale of Two Brain Tumors: Primary versus Metastatic CNS Tumors

Time:
Location:
Co-Chairs:

5:15 – 6:30 p.m.
National Harbor 10-11
Hideho Okada, MD, PhD – University of California, San Francisco
David Reardon, MD – Dana-Farber Cancer Institute

5:15 p.m.

Immunobiology of Primary CNS Tumors
Robert Prins, PhD – University of California, Los Angeles

5:35 p.m.

Immunobilogy of CNS Metastatic Tumors
Harriet M. Kluger, MD – Yale School of Medicine

5:55 p.m.

Difference Between the Application of Adoptive Cellular Therapy for Primary versus Metastatic Tumors
Richard M. Sherry, MD – National Institutes of Health

6:15 p.m.

(O22) Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastoma
Daniela Bota, MD, PhD – University of California Irvine

Concurrent Session 312: NK Cells: From Basic Science to Clinical Application

Time:
Location:
Co-Chairs:

5:15 – 6:30 p.m.
Potomac Ballroom AB
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai
David Raulet, PhD – University of California, Berkeley

5:15 p.m.

Basic Science
Eric Vivier, DVM, PhD – Aix Marseille University, Publique de Hôptiaux de Marseille, Innate-Pharma

5:35 p.m.

no_symbol.pngNatural Killer cells are Susceptible to Effector cell Dysfunction 
in Human Bladder Cancer 
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai

5:55 p.m.

no_symbol.pngMobilization of Natural Killer Cells for Immunotherapy of Cancer
David Raulet, PhD – University of California, Berkeley

6:15 p.m.

(O6) Enhanced presence of a myeloid-like NK cell subpopulation is associated with MHC class I-deficient tumor escape
Yimin Du, PhD – Salk Institute for Biological Studies

Concurrent Session 313: Immunotherapy Advances in Skin Cancer

Time:
Location:
Co-Chairs:

5:15 – 6:30 p.m.
Cherry Blossom Ballroom
Shailender Bhatia, MD – University of Washington
Paolo Antonio Ascierto, MD – Istituto Nazionale Tumori-Fondazione 'G. Pascale'

5:15 p.m.

Immunotherapy Advances in Non-Melanoma Skin Cancer
Shailender Bhatia, MD – University of Washington

5:35 p.m.

Advances in Melanoma Adjuvant Therapy: Implications for Clinical Practice and Future Research
Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and
Research Institute

5:55 p.m.

Immunotherapy Advances in Melanoma
Paolo Antonio Ascierto, MD – Istituto Nazionale Tumori-Fondazione 'G. Pascale'

6:15 p.m.

(O34) Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High Risk Resectable Melanoma (MEL): Preliminary Results
Diwakar Davar, MD – UPMC Hillman Cancer Center

Concurrent Session 314: Tumor and Stromal Cell Biology

Time:
Location:
Co-Chairs:

5:15 – 6:30 p.m.
Potomac Ballroom CD
Kwok-Kin Wong, MD, PhD – New York Langone Health
Neta Erez, PhD – Tel Aviv University

5:15 p.m.

no_symbol.pngIn the Wnt-er of Life: How Wnt Signaling in the Tumor Microevironment Drives Age-Related Tumor Progression
Ashani Weeraratna, PhD – The Wistar Institute

5:35 p.m.

Tumor Microenvironment
Rosandra Kaplan, MD – National Institutes of Health, National Cancer Institute

5:55 p.m.

Pancreatic Cancer
David Tuveson, MD, PhD – Cold Spring Harbor Laboratory 

6:15 p.m.

(O74) Fibroblast activation protein is expressed by human and murine leukocytes and nonspecific inhibition of FAP enhances anti-PD-1 therapy in murine models of PDAC
Allison Fitzgerald, MD/PhD Candidate – Georgetown University

Award Ceremony

Time:
Location:

6:30 – 7:00 p.m.
Prince George's Exhibition Hall C

Poster Reception

Time:
Location:

7:00 – 8:30 p.m.
Prince George's Exhibition Hall AB

The Checkpoints Band Party

Time:
Location:

8:30 – 11:30 p.m.
Riverview Ballroom

Sunday, Nov. 10, 2019

8:00 a.m.

Organizer Welcome
Marianne Davies, DNP, AOCNP – Yale School of Nursing

Session 400: Innovations in Cellular Therapy for Therapeutically Targeting Advanced Malignancies

Time:
Location:
Co-Chairs:

8:05 10:15 a.m.
Prince George's Exhibition Hall C
Michel Sadelain, MD, PhD – Memorial Sloan Kettering Cancer Center
Ingunn Stromnes, PhD – University of Minnesota

8:05 a.m. no_symbol.pngTargeting Neoantigens
Christopher A. Klebanoff, MD – Memorial Sloan Kettering Cancer Center

8:25 a.m.

no_symbol.pngDual Targeting CAR T cell
Crystal Mackall, MD – Stanford University

8:45 a.m. no_symbol.pngEarly Stage Cellular Therapy Trials
Katyoun Rezvani, MD, PhD – University of Texas MD Anderson Cancer Center
9:05 a.m.

no_symbol.pngGene Editing
Avery D. Posey, Jr., PhD – University of Pennsylvania

9:25 a.m. no_symbol.pngNK Cell Therapy: Individual Donor Products to Off-the-Shelf Multi-Dosing Strategies
Jeffrey S. Miller, MD – University of Minnesota
9:45 a.m. no_symbol.png(O51) Sirt2 inhibition enhances anti-tumor immunity by promoting T cell metabolism
Imene Hamaidi, PhD – Moffit Cancer Center

10:00 a.m. (O5) The road-map to Tumor-Infiltrating Lymphocyte (TIL) therapy: Understanding genetic alterations for improved patient treatment
Caitlin Creasy – MD Anderson Cancer Center, UTHealth GSBS

Session 401: Update Session
Time:
Location:
10:30 11:00 a.m.
Prince George's Exhibition Hall C
10:30 a.m. Food and Drug Administration Update
Marc Theoret, MD – U.S. Food and Drug Administration, OHOP

Session 402: Hot Topic Symposium: Modifiable Host Factors and Immune Response

Time:
Location:
Co-Chairs:
11:00 a.m. – 12:30 p.m.
Prince George's Exhibition Hall C
Jennifer A. Ligibel, MD – Dana-Farber Cancer Institute
Jennifer McQuade, MD, MS, MA, LAc – The University of Texas MD Anderson Cancer Center

11:00 a.m. Introduction
Jennifer A. Ligibel, MD – Dana-Farber Cancer Institute
11:10 a.m. no_symbol.pngFiber/Microbiome
Jennifer McQuade, MD, MS, MA, LAc – The University of Texas MD Anderson Cancer Center
11:30 a.m. Obesity
William J. Murphy, PhD – University of California, Davies
11:50 a.m.

Exercise
Connie J. Rogers, PhD, MPH – The Pennsylvania State University

12:10 p.m. no_symbol.pngPanel Discussion
Moderator
Jennifer A. Ligibel, MD – Dana-Farber Cancer Institute

Panelists:
Jennifer McQuade, MD, MS, MA, LAc
– The University of Texas MD Anderson Cancer Center
William J. Murphy, PhD – University of California, Davies
Connie J. Rogers, PhD, MPH – The Pennsylvania State University

​​​​​​​​​​​​​​​​​​​​